<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03969901</url>
  </required_header>
  <id_info>
    <org_study_id>7655A-021</org_study_id>
    <secondary_id>MK-7655A-021</secondary_id>
    <secondary_id>2019-000338-20</secondary_id>
    <nct_id>NCT03969901</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)</brief_title>
  <official_title>A Phase 2/3 Open-label, Randomized, Active-controlled Clinical Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of MK-7655A in Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and tolerability of
      imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of
      age with confirmed or suspected gram-negative bacterial infection. Participants are expected
      to require hospitalization through completion of intravenous (IV) study intervention, and
      have at least one of the following primary infection types: hospital-acquired bacterial
      pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP); complicated
      intra-abdominal infection (cIAI); or complicated urinary tract infection (cUTI). Participants
      will be randomized in a 3:1 ratio to receive IMI/REL or active control. This study will also
      evaluate the efficacy of IMI/REL by assessing all-cause mortality at Day 28
      post-randomization, as well as clinical and microbiological response to treatment. It will
      also evaluate the pharmacokinetics of IMI/REL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">November 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 13, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With One or More Adverse Event (AE)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants with AEs will be presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Medication Due to an Adverse Event (AE)</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study medication due to an AE will be presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths by All Causes Through Day 28</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>All-cause mortality up to 28 days post-randomization will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Clinical Response at End of Therapy (EOT)</measure>
    <time_frame>Day 5 up to Day 14</time_frame>
    <description>The percentage of participants with a favorable clinical response at EOT will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Clinical Response at Early Follow-Up (EFU)</measure>
    <time_frame>Day 12 up to Day 28</time_frame>
    <description>The percentage of participants with a favorable clinical response at EFU will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Clinical Response at Late Follow-Up (LFU)</measure>
    <time_frame>Day 19 up to Day 42</time_frame>
    <description>The percentage of participants with a favorable clinical response at LFU will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Microbiological Response at End of Therapy (EOT)</measure>
    <time_frame>Day 5 up to Day 14</time_frame>
    <description>The percentage of participants with a favorable microbiological response at EOT will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Microbiological Response at End of Follow-Up (EFU)</measure>
    <time_frame>Day 12 up to Day 28</time_frame>
    <description>The percentage of participants with a favorable microbiological response at EFU will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Favorable Microbiological Response at Late Follow-Up (LFU)</measure>
    <time_frame>Day 19 up to Day 42</time_frame>
    <description>Percentage of participants with a favorable microbiological response at LFU will be presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time 0 to 24 Hours (AUC0-24) of Imipenem Following Administration of IMI/REL</measure>
    <time_frame>On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</time_frame>
    <description>Blood samples for AUC0-24 of imipenem analysis will be collected on Day 1 at 30 minutes prior to start of first dose of IV study intervention, within 10 minutes after the end of the first infusion, and 2 to 6 hours after the start of first infusion; and once at the on-therapy (OTX) visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time 0 to 24 Hours (AUC0-24) of Relebactam Following Administration of IMI/REL</measure>
    <time_frame>On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</time_frame>
    <description>Blood samples for AUC0-24 of relebactam analysis will be collected on Day 1 at 30 minutes prior to start of first dose of IV study intervention, within 10 minutes after the end of the first infusion, and 2 to 6 hours after the start of first infusion; and once at the on-therapy (OTX) visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at End of Infusion (Ceoi) of Imipenem Following Administration of IMI/REL</measure>
    <time_frame>At the end of the first infusion on Day 1.</time_frame>
    <description>Blood samples for Ceoi of imipenem analysis will be collected within 10 minutes after the end of the first infusion on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at End of Infusion (Ceoi) of Relabactam Following Administration of IMI/REL</measure>
    <time_frame>At the end of the first infusion on Day 1.</time_frame>
    <description>Blood samples for Ceoi of relabactam analysis will be collected within 10 minutes after the end of the first infusion on Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Imipenem Concentration Is Above Minimum Inhibitory Concentration (%T&gt;MIC of Imipenem) Following Administration of IMI/REL</measure>
    <time_frame>On Day 1 at 30 minutes prior to start of first IV infusion of study drug, at end of first infusion, and 2 to 6 hours after start of first infusion; and once at on-therapy visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</time_frame>
    <description>Blood samples for %T&gt;MIC of imipenem analysis will be collected on Day 1 at 30 minutes prior to start of first dose of IV study intervention, within 10 minutes after the end of the first infusion, and 2 to 6 hours after the start of first infusion; and once at the on-therapy (OTX) visit (Day 2 or Day 3) at 2 to 6 hours after start of any infusion that day.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Suspected or Documented Gram-negative Bacterial Infection</condition>
  <arm_group>
    <arm_group_label>IMI/REL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with cIAI or cUTI will receive imipenem/cilastatin/relebactam (IMI/REL) via IV infusion, once every 6 hours, for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive IMI/REL via IV infusion, once every 6 hours, for a minimum of 7 days up to a maximum of 14 days. All oral switch medications will be chosen from a list of acceptable approved agents and will be administered per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with cIAI or cUTI will receive active control via IV infusion for a minimum of 5 days (with optional oral switch after 3 days) up to a maximum of 14 days. Participants with HABP/VABP will receive active control via IV infusion for a minimum of 7 days up to a maximum of 14 days. All active control and oral switch medications will be administered per authorized PI, SPC, or international treatment guidelines. All active control and oral switch medications will be chosen from a list of acceptable approved agents.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMI/REL</intervention_name>
    <description>Age-based dosing:
12 to &lt;18 years, IMI 500 and REL 250 mg, IV infusion every 6 hours
2 to &lt;12 years, IMI 15 and REL 7.5 mg/kg, IV infusion every 6 hours
3 months to &lt;2 years, to be determined (TBD)
Birth to &lt;3 months (TBD) NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention.</description>
    <arm_group_label>IMI/REL</arm_group_label>
    <other_name>MK-7655A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Control</intervention_name>
    <description>All active control medications will be chosen from a list of acceptable approved agents for each infection type (HABP or VABP, cIAI, and UTI) and will be given via IV infusion, per authorized Package Insert (PI), Summary of Product Characteristics (SPC), or international treatment guidelines.
NOTE: Participants with cIAI or cUTI may be switched to oral therapy after at least 3 days of IV study intervention. All oral switch medications will be chosen from a list of acceptable approved agents.</description>
    <arm_group_label>Active Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requires hospitalization and treatment with IV antibacterial therapy for confirmed or
             suspected gram-negative bacterial infection (in the absence of meningitis), and is
             expected to require hospitalization through completion of IV study intervention, with
             at least 1 of the following primary infection types: HABP or VABP; cIAI; or cUTI.

          -  For Age Cohorts 4 and 5, participant is at least 37 weeks postmenstrual age at the
             time of signing the informed consent.

          -  If female, must not be pregnant or breastfeeding, and at least 1 of the following
             conditions must apply: must not be a woman of childbearing potential (WOCBP); OR, if a
             WOCBP, must agree to follow contraceptive guidance during the intervention period and
             for at least 24 hours after the last dose of study intervention.

          -  Has sufficient intravascular access to receive study drug through an existing
             peripheral or central line.

        Exclusion Criteria:

          -  Is expected to survive less than 72 hours.

          -  Has a concurrent infection that would interfere with evaluation of response to the
             study antibacterials (IMI/REL or Active Control), including any of the following:
             endocarditis; osteomyelitis; meningitis; prosthetic joint infection; active pulmonary
             tuberculosis; disseminated fungal infection; concomitant infection at the time of
             randomization that requires non-study systemic antibacterial therapy in addition to IV
             study treatment or oral step-down therapy.

          -  Has HABP/VABP caused by an obstructive process, including lung cancer (or other
             malignancy metastatic to the lungs resulting in pulmonary obstruction) or other known
             obstruction.

          -  Has a cUTI, with any of the following: complete obstruction of any portion of the
             urinary tract (ie, requiring a permanent indwelling urinary catheter or
             instrumentation); documented ileal loop reflux; suspected or confirmed perinephric or
             intrarenal abscess; suspected or confirmed prostatitis, urethritis, or epididymitis;
             trauma to pelvis/urinary tract; presence of indwelling urinary catheter which cannot
             be removed at study entry.

          -  Has any of the following medical conditions at screening: history of a seizure
             disorder (requiring ongoing treatment with anti-convulsive therapy or prior treatment
             with anti-convulsive therapy within the last 3 years); cystic fibrosis; history of
             serious allergy, hypersensitivity (eg, anaphylaxis), or any serious reaction to IMI,
             or to any carbapenem, cephalosporin, penicillin, or other β-lactam agent, or to other
             β-lactamase inhibitors (eg, tazobactam, sulbactam, clavulanic acid, avibactam).

          -  Has a history or current evidence of any condition, therapy, laboratory abnormality,
             or other circumstance that might expose the participant to risk by participating in
             the study, confound study results, or interfere with the participant's participation
             for the full duration of the study.

          -  If less than 3 months of age, has received more than 72 hours of empiric antibacterial
             treatment until meningitis has been ruled out prior to initiation of IV study
             intervention.

          -  If 3 months of age or older, has received potentially therapeutic antibacterial
             therapy (eg, with gram-negative activity), including bladder infusions with topical
             urinary antiseptics or antibacterial agents, for a duration of more than 24 hours
             during the 48 hours preceding the first dose of study intervention.

          -  Is anticipated to be treated with any of the following medications: valproic acid or
             divalproex sodium (or has used valproic acid or divalproex sodium in the 2 weeks prior
             to screening) through 24 hours after completion of the final dose of IV study
             intervention for participants who receive IMI/REL or carbapenem; concomitant IV, oral,
             or inhaled antimicrobial agents with gram-negative activity, in addition to those
             designated in the study intervention groups, during the course of all (IV/oral) study
             intervention; planned receipt of suppressive/prophylactic antibiotics with
             gram-negative activity after completion of study intervention.

          -  Is currently participating in or has participated in an interventional clinical study
             with an investigational compound or device within 30 days prior to screening.

          -  Has enrolled previously in the current study and been discontinued, or has received
             REL for any other reason.

          -  Has an estimated creatinine clearance (based on the Cockcroft-Gault equation, for
             participants ≥12 years of age) or estimated glomerular filtration rate (eGFR, based on
             the modified Schwartz equation, for participants &lt;12 years of age) below that
             specified for the appropriate age range; or requires peritoneal dialysis,
             hemodialysis, or hemofiltration.

          -  Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥5 × upper
             limit of normal (ULN) at the time of screening. NOTE: Patients with acute hepatic
             failure or acute decompensation of chronic hepatic failure should also be excluded.

          -  Is a user of recreational or illicit drugs or has had a recent history of drug or
             alcohol abuse or dependence.

          -  Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or
             child) who is investigational site or Sponsor staff directly involved with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner University Medical Center ( Site 0356)</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>520-237-6845</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miller Children's &amp; Women's Hospital ( Site 0349)</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>562-933-8590</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital-San Diego ( Site 0347)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>858-966-8381</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center-Floating Hospital for Children ( Site 0350)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-636-0186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of New Mexico ( Site 0358)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>505-269-3630</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital ( Site 0360)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-567-5262</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Richmond at VCU ( Site 0359)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>804-628-4571</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University Ruby Memorial Hospital ( Site 0344)</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>304-293-1201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital San Vicente de Paul ( Site 0269)</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573104262042</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa Ltda. ( Site 0264)</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573157609110</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital Infantil Universitario de San Jose ( Site 0268)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573108059791</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Universitaria de Ciencias de la Salud - Sociedad de Cirugia ( Site 0265)</name>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital De Bogota</state>
        <zip>111411</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573207532651</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili ( Site 0266)</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+573154896219</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Francois Mitterand ( Site 0146)</name>
      <address>
        <city>Dijon</city>
        <state>Cote-d'Or</state>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33380295892</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Jeanne de Flandre ( Site 0145)</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59120</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33320446059</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schneider Children's Medical Center ( Site 0187)</name>
      <address>
        <city>Petah Tikva</city>
        <state>HaMerkaz</state>
        <zip>4920235</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97239253779</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center ( Site 0189)</name>
      <address>
        <city>Haifa</city>
        <state>Heifa</state>
        <zip>3525408</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247774810</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 0190)</name>
      <address>
        <city>Ramat Gan</city>
        <state>Tell Abib</state>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235305978</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Hebrew University Medical Center ( Site 0188)</name>
      <address>
        <city>Jerusalem</city>
        <state>Yerushalayim</state>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226777111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Tijuana ( Site 0284)</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <zip>22320</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5216643191464</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centenario Hospital Miguel Hidalgo ( Site 0290)</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20259</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+5217085453931</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria ( Site 0291)</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+525510840900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of the Philippines-Philippine General Hospital ( Site 0318)</name>
      <address>
        <city>Manila</city>
        <state>National Capital Region</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639178321832</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philippine Children s Medical Center ( Site 0317)</name>
      <address>
        <city>Quezon City</city>
        <state>National Capital Region</state>
        <zip>1104</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+639178951457</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital Zespolony im. Rydgiera ( Site 0220)</name>
      <address>
        <city>Torun</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48566794601</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki ( Site 0223)</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48422711391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 0226)</name>
      <address>
        <city>Lomianki</city>
        <state>Mazowieckie</state>
        <zip>05-092</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48227657153</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Hematology Oncology and Immunology Centre n.a. D.Rogachev. ( Site 0233)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>117197</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79161666692</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Morozovskaya Children City Clinical Hospital ( Site 0241)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79255858745</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.Petersburg State Pediatric Medical University ( Site 0236)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>194100</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79219536683</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's City Clinical Hospital #1 ( Site 0237)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>198205</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79213210974</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children s City Clinical Hospital 5 n.a. N.F. Filatov ( Site 0235)</name>
      <address>
        <city>St. Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>192289</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78124000410</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Smolensk Regional Clinical Hospital ( Site 0231)</name>
      <address>
        <city>Smolensk</city>
        <state>Smolenskaya Oblast'</state>
        <zip>214018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79107896781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Childrens Clinical Hospital ( Site 0400)</name>
      <address>
        <city>Vologda</city>
        <state>Vologodskaya Oblast'</state>
        <zip>160022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+79201256440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris Hani Baragwanath Academic Hospital ( Site 0156)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27827831496</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Empilweni Services and Research Unit ( Site 1557)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2093</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27114709000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sefako Makgatho Health Sciences University ( Site 0155)</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0208</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27727967684</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Universitario Nino Jesus ( Site 0114)</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34915035900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0113)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34912071551</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio ( Site 0115)</name>
      <address>
        <city>Sevilla</city>
        <zip>41043</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34677910643</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cukurova University Medical Faculty ( Site 0200)</name>
      <address>
        <city>Adana</city>
        <zip>01330</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905326534166</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara Universitesi Tip Fakultesi. ( Site 0202)</name>
      <address>
        <city>Ankara</city>
        <zip>06590</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905322534538</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eskisehir Osmangazi University Medical ( Site 0201)</name>
      <address>
        <city>Eskisehir</city>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905339243269</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBU Sariyer Hamidiye Etfal Egitim ve Arastirma Hastanesi ( Site 0198)</name>
      <address>
        <city>Istanbul</city>
        <zip>34453</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905055803297</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege Universitesi Tıp Fakultesi Hastanesi ( Site 0199)</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+902323901427</phone>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>May 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MK-7655</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

